RT Avi Chawla (@_avichawla)Finally, a browser automation framework for Agents that actually works in production (open-source)!Typical browser automation tools like Selenium or Playwright require you to hard-code automation. These are brittle since one change in the website can disrupt the full workflow.On the other hand, high-level Agents like OpenAI Operator can be unpredictable in production.Stagehand is an open-source framework that bridges the gap between:- brittle traditional automation like Playwright ...

NEW YORK, July 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation aligns with his executive employment agreement and comes at a critical time for the company [2] - The company has not yet appointed a successor for the CFO position, creating uncertainty as it faces market and legal challenges [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has significantly underperformed, leading to a downward revision of the company's full-year revenue projections [3][6] - The first-quarter sales figures for Amtagvi fell short of Wall Street expectations, prompting a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is facing a class-action securities fraud lawsuit related to its claims about authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5] - The lawsuit alleges discrepancies between the company's public statements about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock price dropped over 44%, from $3.17 to $1.75 per share within a day [7]

Core Insights - Quantum computers have the potential to revolutionize industries by performing complex calculations much faster than current supercomputers [1] - D-Wave Quantum and IonQ are two companies in the quantum computing sector that present intriguing investment opportunities, but their performance and strategies differ significantly [2] D-Wave Quantum - D-Wave's stock has increased over 90% in 2025, reaching a 52-week high of $19.77 in May, driven by a 509% year-over-year increase in Q1 revenue to $15 million, surpassing its total sales of $8.8 million for all of 2024 [4][5] - The revenue surge was attributed to the first sale of its proprietary Advantage quantum machine, shifting from a previous reliance on quantum computing as a service (QCaaS) [5] - D-Wave's Q1 operating loss improved to $11.3 million from $17.5 million in 2024, with total assets of $325.6 million, including $304.3 million in cash, and liabilities of $118.2 million [6] - The company has sufficient cash reserves, approximately $815 million after an equity offering, to sustain operations until profitability, with some funds allocated for acquisitions [7] IonQ - IonQ's stock performance has been less impressive, with a 9% increase through July 9, attributed to disappointing Q1 results [8] - Q1 revenue was flat at $7.6 million compared to 2024, while operating losses increased to $75.7 million from $52.9 million the previous year [9] - IonQ maintains a strong balance sheet with total Q1 assets of $850.1 million and liabilities of $85 million, and announced a $1 billion equity offering to bolster finances [10] - The company is focused on building a quantum computing network, which is costly and requires acquiring various capabilities, such as the recent acquisition of Lightsynq Technologies [11] Comparative Analysis - D-Wave claims to be the sole provider of both quantum gate technology and quantum annealing, while IonQ is pursuing a network-building strategy [12] - The long-term success of either company remains uncertain, with potential competition from larger players like Microsoft [13] - D-Wave's impressive Q1 results may not be sustainable, as they represent a shift from its traditional revenue model [14] - IonQ, despite a slow start in 2025, reported a 95% year-over-year revenue growth to $43.1 million by the end of 2024 and projects sales between $75 million and $95 million for 2025 [15] - Valuation metrics indicate that both D-Wave and IonQ have higher price-to-sales (P/S) ratios compared to Microsoft, suggesting potential overvaluation [16] Investment Strategy - Given the high valuations and uncertainty in the quantum computing sector, it may be prudent to wait for Q2 earnings reports to assess the sustainability of D-Wave's Q1 results and IonQ's recovery potential [18]

数字原生代掀起科技风暴 全球极客盛宴再启新章 在代码与创意碰撞的数字时代，Z世代正以颠覆性的创造力重新定义技术边界。2023年，由两位00后极客领衔发起的AdventureX 全球黑客马拉松，以其独特的青春视角点燃了全球技术社群的热情。这场被誉为 "开发者世界杯"的顶级赛事， 不仅云集了六大洲的 新锐程序员，更凭借其开放共享的极客文化与突破性的项目孵化机制，持续刷新着人们对年轻一代技术能力的认知。 从硅谷到中关 村， 这场持续72小时的数字狂欢正在书写属于新一代技术领袖的传奇。 从校园到世界： AdventureX的成长之路 AdventureX的故事始于两位00后高中生—— 朱浩宇和徐晨 的大胆构想。在高二那年，他们萌发了一个为国内年轻人打造黑客松的 创意，并立即付诸行动，组建起一支充满活力的年轻团队。 经过九个月的艰苦奋斗，这个年轻的团队创造了令人瞩目的成绩：从零起步筹集到百万元赞助资金，成功邀约百余位来自科技和创 投领域的顶尖嘉宾。首届活动便吸引了全球182个国家和地区的近4500名参赛者，参赛群体涵盖中学生、大学生及年轻开发者等多 元背景。 今年，AdventureX实现全新突破：规模持续扩大，场地全 ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, which is administered at authorized treatment centers (ATCs) [3]. Group 2: Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Group 3: Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Viewpoint - Meta Platforms is experiencing strong operating performance driven by investments in AI, leading to stock trading near record highs and expectations for a robust second-quarter financial report [2][8]. Group 1: AI Impact on Business - Meta has become a leading platform for advertisers, reaching over 3.4 billion daily users across its social media platforms, which enhances its advertising revenue [4]. - The company has developed an AI algorithm that personalizes content for users, resulting in a 6% increase in time spent on Instagram and a 7% increase on Facebook over six months [5]. - Meta AI, launched in 2023, has nearly 1 billion monthly active users, showcasing its rapid adoption and effectiveness [6]. Group 2: Financial Performance - In Q1 2025, Meta reported total revenue of $42.3 billion, a 16% increase year-over-year, and earnings per share (EPS) of $6.43, up 37% [8]. - Management guidance suggests Q2 revenue will be between $42.5 billion and $45.5 billion, indicating continued growth [8]. - Wall Street estimates predict an EPS of around $5.84 for Q2, reflecting a more modest increase of approximately 13% due to significant AI investments [9]. Group 3: Capital Expenditures and Future Outlook - Meta plans to spend between $64 billion and $72 billion on AI infrastructure and chips in 2025, an increase from previous estimates [10]. - This capital expenditure may impact short-term earnings but is expected to drive long-term growth as AI investments mature [11]. - An increase in the capex forecast could signal management's confidence in AI's transformative potential for the business [11]. Group 4: Investment Considerations - Meta's current price-to-earnings (P/E) ratio is 28.3, making it cheaper than the Nasdaq-100 index at 32.3, positioning it as an attractive investment [12]. - The stock is considered a good buy ahead of the upcoming financial report, especially for long-term investors [14].

智通财经APP获悉，据媒体看到的一份内部备忘录，Meta(META.US)完成了对于专注AI语音技术的小型 AI初创公司PlayAI的收购进程，"整个 PlayAI 团队"将于下周加入Facebook母公司Meta(META.US)。据了 解，PlayAI团队届时将向约翰·沙尔奎克(Johan Schalkwyk)汇报——后者近期刚从另一家聚焦于AI语音的 AI初创公司Sesame AI Inc.加盟 Meta。 Meta掌舵者扎克伯格的"AI雄心壮志"可谓再添一关键拼图。扎克伯格将大举推进人工智能技术更新迭代 以及将AI推进至Meta软件生态，列为Meta今年的首要任务，正斥资约650亿美元大举投资AI服务器集 群、高性能以太网交换机系统等AI核心基础设施，并且积极招募全球最顶尖人才以构建全球最强大AI 模型以及筑建起强大的基于Meta体系的AI应用软件生态。 据了解，Meta首席执行官马克·扎克伯格近期宣布对该公司AI业务部门进行重大重组，任命前Scale AI首 席执行官亚历山大·王(Alexandr Wang)领导新成立的Meta超级智能团队(Meta Superintelligence Labs)。 ...

Finally, a browser automation framework for Agents that actually works in production (open-source)!Typical browser automation tools like Selenium or Playwright require you to hard-code automation. These are brittle since one change in the website can disrupt the full workflow.On the other hand, high-level Agents like OpenAI Operator can be unpredictable in production.Stagehand is an open-source framework that bridges the gap between:- brittle traditional automation like Playwright, Selenium, etc. and- unpre ...

WEST PALM BEACH, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2026 first quarter results. FISCAL 2026 FIRST QUARTER HIGHLIGHTS – Net sales decreased 32% to approximately $2.70 million in the fiscal 2026 first quarter versus $3.97 million in the fiscal 2025 first quarter.Net bookings increased 37% to $2.80 million in the fiscal 2026 first quarter versus $2.04 million in the prior year first quarter.Backlog increas ...